TICKERNERD
Menu
GNLXGNLXHealthcare · Biotechnology

GNLX Stock Forecast: Genelux Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.71
−1.09% on the day

The 6 Wall Street analysts covering Genelux Corp. hold a median 12-month price target of $16 — +490.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$123.1M
Ticker Nerd rank
19 / 100
Median analyst target
$16
Analysts covering
6
Total return, dividends reinvested
1W
−1.1%
1M
−6.2%
YTD
−37.8%
1Y
−21.2%
From 52W high
−67.1%
From 52W low
+17.8%
$2.30
$8.24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GNLX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Genelux Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
75
Size
74
Volatility
43
Revisions
40
Growth
29
Value
25
Momentum
21
Quality
19
Issuance
16

Accruals (75): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GNLX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GNLX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00$35.00Oct 25Jan 26Apr 26Jul 26GNLXHigh $31Median $16Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $10Median $16High $31

The green dot is the last close — the median target sits +490.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Mar 2026BenchmarkMaintainsSpeculative Buy$23 → $20
21 Oct 2025Lake StreetInitiatesBuy—
21 July 2025LUCID CAPITAL MARKETSInitiatesBuy—
8 May 2025BenchmarkMaintainsSpeculative Buy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Mar 2025HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.MaintainsBuy—
29 Oct 2024GuggenheimInitiatesBuy—
27 Aug 2024Roth MKMInitiatesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
3 June 2024BenchmarkReiteratesSpeculative Buy—
31 May 2024BenchmarkMaintainsSpeculative Buy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
3 Apr 2024BenchmarkReiteratesSpeculative Buy—
2 Apr 2024HC Wainwright & Co.MaintainsBuy—
27 Nov 2023HC Wainwright & Co.InitiatesBuy—
24 Nov 2023BenchmarkMaintainsSpeculative Buy—
12 Sept 2023Maxim GroupInitiatesBuy—
9 June 2023BenchmarkMaintainsSpeculative Buy—
18 May 2023Brookline CapitalInitiatesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GNLX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GNLX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
4
Fundamentals

Genelux Corp. (GNLX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.2×

Cheaper than 87% of US stocks

Price / sales
15383.4×

Cheaper than 1% of US stocks

Price / book
7.6×

Cheaper than 14% of US stocks

EV / EBITDA
−2.9×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−455275.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−177.9%

Higher than 8% of US stocks

Return on assets
−77.9%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GNLX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GNLXGenelux Corp.$123.1M
19
HURATuHURA Biosciences, Inc.$121.4M
17
INOInovio Pharmaceuticals, Inc.$121.9M
44
NAUTNautilus Biotechnology, Inc.$121.3M
55
RANIRani Therapeutics Holdings, Inc.$120.0M
64
GUTSFractyl Health, Inc.$123.7M
30
ANIXAnixa Biosciences, Inc.$124.4M
85

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Genelux Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GNLX news & analysis

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

GlobeNewsWire · 13 Aug 2026neutral

Genelux Corporation reported its second quarter financial results and provided business updates. The company stated that topline data from the Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec is expected in the second half of 2026, and additional dose-escalation updates for Olvi-Vec systemic development programs are anticipated in 2026.

Why it matters — Genelux watchers would track these announced timelines for Olvi-Vec's pivotal ovarian cancer trial data and systemic program updates as key near-term milestones for the company's pipeline.

FAQ

Frequently asked questions about GNLX stock

What is the GNLX stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Genelux Corp. have a median 12-month price target of $16, with estimates ranging from $10 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GNLX stock a buy right now?

Of the 6 analysts covering Genelux Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Genelux Corp. 19 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GNLX?

As at 22 Aug 2026, Genelux Corp. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (75 of 100).

Will GNLX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +490.4% from the last close, and Ticker Nerd's factor model ranks Genelux Corp. 19 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GNLX stock forecast for 2030?

No analyst covering Genelux Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GNLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $31 over the next 12 months.

How has GNLX stock performed over the past year?

Genelux Corp. returned -21.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Genelux Corp. do?

Genelux Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients with aggressive or difficult-to-treat solid tumor types.

What is the latest news on GNLX?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates". Genelux Corporation reported its second quarter financial results and provided business updates. The company stated that topline data from the Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec is expected in the second half of 2026, and additional dose-escalation updates for Olvi-Vec systemic development programs are anticipated in 2026.

Company

About Genelux Corp.

Genelux Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients with aggressive or difficult-to-treat solid tumor types. Its lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary modified strain of the vaccinia virus designed to selectively target and destroy cancer cells while stimulating immune responses. The company leverages its proprietary CHOICE discovery and development platform to engineer an extensive library of oncolytic vaccinia virus candidates with immune modulatory and enhanced cell-killing properties. Genelux Corp. targets cancers such as ovarian, lung, and pancreatic, addressing unmet needs in immuno-oncology through innovative virotherapy approaches. Operations are based in Southern California, with headquarters in Westlake Village. Founded in 2001, Genelux Corp. emphasizes clinical advancement of its pipeline to provide safe and effective treatments for solid tumors.

CEO Mr. Thomas D. Zindrick J.D. · 25 employees · United States · https://www.genelux.com